vs
Side-by-side financial comparison of CROSS COUNTRY HEALTHCARE INC (CCRN) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $236.8M, roughly 1.2× CROSS COUNTRY HEALTHCARE INC). Bio-Techne runs the higher net margin — 12.8% vs -35.0%, a 47.9% gap on every dollar of revenue. On growth, Bio-Techne posted the faster year-over-year revenue change (-6.4% vs -23.6%). Over the past eight quarters, Bio-Techne's revenue compounded faster (4.2% CAGR vs -21.0%).
GE Healthcare Technologies, Inc. is an American health technology company based in Chicago, Illinois. The company, which stylizes its own name as GE HealthCare, operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical ...
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CCRN vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $236.8M | $295.9M |
| Net Profit | $-82.9M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -30.2% | 18.4% |
| Net Margin | -35.0% | 12.8% |
| Revenue YoY | -23.6% | -6.4% |
| Net Profit YoY | -2109.7% | 68.3% |
| EPS (diluted) | $-2.56 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $236.8M | $295.9M | ||
| Q3 25 | $250.1M | — | ||
| Q2 25 | $274.1M | $317.0M | ||
| Q1 25 | $293.4M | $316.2M | ||
| Q4 24 | $309.9M | $297.0M | ||
| Q3 24 | $315.1M | $289.5M | ||
| Q2 24 | $339.8M | $306.1M | ||
| Q1 24 | $379.2M | $303.4M |
| Q4 25 | $-82.9M | $38.0M | ||
| Q3 25 | $-4.8M | — | ||
| Q2 25 | $-6.7M | $-17.7M | ||
| Q1 25 | $-490.0K | $22.6M | ||
| Q4 24 | $-3.8M | $34.9M | ||
| Q3 24 | $2.6M | $33.6M | ||
| Q2 24 | $-16.1M | $40.6M | ||
| Q1 24 | $2.7M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | 20.4% | — | ||
| Q2 25 | 20.4% | 62.7% | ||
| Q1 25 | 20.0% | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | 20.4% | 63.2% | ||
| Q2 24 | 20.8% | 66.4% | ||
| Q1 24 | 20.4% | 67.4% |
| Q4 25 | -30.2% | 18.4% | ||
| Q3 25 | -2.4% | — | ||
| Q2 25 | -2.1% | -7.5% | ||
| Q1 25 | -0.3% | 12.2% | ||
| Q4 24 | -1.1% | 16.0% | ||
| Q3 24 | 0.9% | 13.8% | ||
| Q2 24 | -5.7% | 15.0% | ||
| Q1 24 | 0.8% | 22.1% |
| Q4 25 | -35.0% | 12.8% | ||
| Q3 25 | -1.9% | — | ||
| Q2 25 | -2.4% | -5.6% | ||
| Q1 25 | -0.2% | 7.1% | ||
| Q4 24 | -1.2% | 11.7% | ||
| Q3 24 | 0.8% | 11.6% | ||
| Q2 24 | -4.7% | 13.3% | ||
| Q1 24 | 0.7% | 16.2% |
| Q4 25 | $-2.56 | $0.24 | ||
| Q3 25 | $-0.15 | — | ||
| Q2 25 | $-0.20 | $-0.11 | ||
| Q1 25 | $-0.02 | $0.14 | ||
| Q4 24 | $-0.13 | $0.22 | ||
| Q3 24 | $0.08 | $0.21 | ||
| Q2 24 | $-0.47 | $0.26 | ||
| Q1 24 | $0.08 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $108.7M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $322.8M | $2.0B |
| Total Assets | $449.0M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $108.7M | $172.9M | ||
| Q3 25 | $99.1M | — | ||
| Q2 25 | $81.2M | $162.2M | ||
| Q1 25 | $80.7M | $140.7M | ||
| Q4 24 | $81.6M | $177.5M | ||
| Q3 24 | $64.0M | $187.5M | ||
| Q2 24 | $69.6M | $152.9M | ||
| Q1 24 | $5.2M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $322.8M | $2.0B | ||
| Q3 25 | $408.1M | — | ||
| Q2 25 | $412.2M | $1.9B | ||
| Q1 25 | $418.2M | $2.0B | ||
| Q4 24 | $419.0M | $2.1B | ||
| Q3 24 | $424.7M | $2.1B | ||
| Q2 24 | $433.3M | $2.1B | ||
| Q1 24 | $462.4M | $2.0B |
| Q4 25 | $449.0M | $2.5B | ||
| Q3 25 | $538.2M | — | ||
| Q2 25 | $553.8M | $2.6B | ||
| Q1 25 | $576.2M | $2.6B | ||
| Q4 24 | $589.3M | $2.7B | ||
| Q3 24 | $597.4M | $2.7B | ||
| Q2 24 | $602.9M | $2.7B | ||
| Q1 24 | $648.4M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $18.2M | — |
| Free Cash FlowOCF − Capex | $16.1M | — |
| FCF MarginFCF / Revenue | 6.8% | — |
| Capex IntensityCapex / Revenue | 0.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.2M | — | ||
| Q3 25 | $20.1M | — | ||
| Q2 25 | $4.2M | $98.2M | ||
| Q1 25 | $5.7M | $41.1M | ||
| Q4 24 | $24.2M | $84.3M | ||
| Q3 24 | $7.5M | $63.9M | ||
| Q2 24 | $82.4M | $75.5M | ||
| Q1 24 | $6.0M | $81.0M |
| Q4 25 | $16.1M | — | ||
| Q3 25 | $17.9M | — | ||
| Q2 25 | $2.3M | $93.3M | ||
| Q1 25 | $3.8M | $31.0M | ||
| Q4 24 | $21.7M | $77.5M | ||
| Q3 24 | $6.3M | $54.7M | ||
| Q2 24 | $79.6M | $57.5M | ||
| Q1 24 | $3.8M | $64.5M |
| Q4 25 | 6.8% | — | ||
| Q3 25 | 7.2% | — | ||
| Q2 25 | 0.8% | 29.4% | ||
| Q1 25 | 1.3% | 9.8% | ||
| Q4 24 | 7.0% | 26.1% | ||
| Q3 24 | 2.0% | 18.9% | ||
| Q2 24 | 23.4% | 18.8% | ||
| Q1 24 | 1.0% | 21.3% |
| Q4 25 | 0.9% | — | ||
| Q3 25 | 0.9% | — | ||
| Q2 25 | 0.7% | 1.5% | ||
| Q1 25 | 0.6% | 3.2% | ||
| Q4 24 | 0.8% | 2.3% | ||
| Q3 24 | 0.4% | 3.2% | ||
| Q2 24 | 0.8% | 5.9% | ||
| Q1 24 | 0.6% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | 2.92× | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | 2.23× | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CCRN
| Temporary Staffing Services | $189.6M | 80% |
| Physician Staffing | $42.5M | 18% |
| Other Services | $4.7M | 2% |
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
